ArticleFrontiers in cellular and infection microbiology2026
Repeated dose toxicity and immunogenicity studies in SD rats: a new recombinant zoster vaccine (CHO cell) formulated with adjuvant BC02.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster, an infectious disease resulting from the reactivation of the varicella-zoster virus, is characterized by intense neuropathic pain. Safe and effective vaccination remains the optimal strategy for preventing and reducing associated complications. Recombinant zoster vaccine (CHO cell) (Qiuhong et al) employs a novel adjuvant system, BC02. This study aimed to conduct a comprehensive non-clinical safety assessment of RZV in adult Sprague-Dawley rats to support its entry into clinical trials. The rats received four (sp, one additional dose beyond the intended clinical three-dose schedule) doses of RZV. Safety was assessed using general health observations, immunotoxicity and immunogenicity assays, hematological and biochemical profiling, and histopathological evaluations. Aside from the changes observed in the adjuvant control group, no significant toxic effects were detected. No distinct target organs of toxicity were identified. The no-observed-adverse-effect level (NOAEL) was 1.0 mL per rat, which is equivalent to two human doses. The vaccine also elicited strong cellular and humoral responses, indicating its favorable immunogenicity. In summary, this systematic toxicology program supports the safety, tolerability, and immunogenicity of RZV and justifies its progression to human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.